Comparative genomic analysis of primary and synchronous metastatic colorectal cancers.
Approximately 50% of patients with primary colorectal carcinoma develop liver metastases. Understanding the genetic differences between primary colon cancer and their metastases to the liver is essential for devising a better therapeutic approach for this disease. We performed whole exome sequencing...
Guardado en:
Autores principales: | Sun Young Lee, Farhan Haq, Deokhoon Kim, Cui Jun, Hui-Jong Jo, Sung-Min Ahn, Won-Suk Lee |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Public Library of Science (PLoS)
2014
|
Materias: | |
Acceso en línea: | https://doaj.org/article/b148a487092443c08cd2061b58566faf |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Bevacizumab plus capecitabine as later-line treatment for patients with metastatic colorectal cancer refractory to irinotecan, oxaliplatin, and fluoropyrimidines
por: Yeong Hak Bang, et al.
Publicado: (2021) -
Implication of FDG-PET/CT without synchronous colonic lesion in patients with stenotic left-sided colorectal cancer
por: Jong Il Lee, et al.
Publicado: (2021) -
Ziv-aflibercept in metastatic colorectal cancer
por: Patel A, et al.
Publicado: (2013) -
Comparison of prognostic genomic predictors in colorectal cancer.
por: Yun-Yong Park, et al.
Publicado: (2013) -
Bevacizumab in the therapy for refractory metastatic colorectal cancer
por: Mary F Mulcahy
Publicado: (2008)